- Title
- Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC Study
- Creator
- Dowsett, Mitch; Cuzick, Jack; Howell, Anthony; Bugarini, Roberto; Baehner, Frederick L.; Shak, Steven; Wale, Christopher; Forbes, John; Mallon, Elizabeth A.; Salter, Janine; Quinn, Emma; Dunbier, Anita; Baum, Michael; Buzdar, Aman
- Relation
- Journal of Clinical Oncology Vol. 28, Issue 11, p. 1829-1834
- Publisher Link
- http://dx.doi.org/10.1200/JCO.2009.24.4798
- Publisher
- American Society of Clinical Oncology
- Resource Type
- journal article
- Date
- 2010
- Description
- Purpose: To determine whether the Recurrence Score (RS) provided independent information on risk of distant recurrence (DR) in the tamoxifen and anastrozole arms of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trial. Patients and Methods: RNA was extracted from 1,372 tumor blocks from postmenopausal patients with hormone receptor positive primary breast cancer in the monotherapy arms of ATAC. Twenty-one genes were assessed by quantitative reverse transcriptase polymerase chain reaction, and the RS was calculated. Cox proportional hazards models assessed the value of adding AS to a model with clinical variables (age, tumor size, grade, and treatment) in node-negative (NO) and node-positive (N+) women. Results: Reportable scores were available from 1,231 evaluable patients (NO, n = 872; N+, n = 306; and node status unknown, n = 53); 72, 74, and six DRs occurred in NO, N+, and node status unknown patients, respectively. For both NO and N+ patients, AS was significantly associated with time to DR in multivariate analyses (P < .001 for NO and P = .002 for N+). AS also showed significant prognostic value beyond that provided by Adjuvant! Online (P < .001). Nine-year DR rates in low (RS < 18), intermediate (RS = 18 to 30), and high RS (RS≥31) groups were 4%, 12%, and 25%, respectively, in NO patients and 17%, 28%, and 49%, respectively, in N+ patients. The prognostic value of AS was similar in anastrozole- and tamoxifen-treated patients. Conclusion: This study confirmed the performance of AS in postmenopausal HR+ patients treated with tamoxifen in a large contemporary population and demonstrated that AS is an independent predictor of DR in NO and N+ hormone receptor positive patients treated with anastrozole, adding value to estimates with standard clinicopathologic features.
- Subject
- breast cancer; chemotherapy; tamoxifen; anastrozole
- Identifier
- http://hdl.handle.net/1959.13/931987
- Identifier
- uon:11225
- Identifier
- ISSN:0732-183X
- Language
- eng
- Reviewed
- Hits: 24287
- Visitors: 9985
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|